Calliditas Therapeutics AB
NASDAQ:CALT

Watchlist Manager
Calliditas Therapeutics AB Logo
Calliditas Therapeutics AB
NASDAQ:CALT
Watchlist
Price: 40.0001 USD Market Closed
Market Cap: $1.1B

Net Margin

-30%
Current
Improving
by 7.9%
vs 3-y average of -37.9%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-30%
=
Net Income
kr-480.4m
/
Revenue
kr1.6B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-30%
=
Net Income
$-480.4m
/
Revenue
kr1.6B

Peer Comparison

Country Company Market Cap Net
Margin
SE
Calliditas Therapeutics AB
STO:CALTX
12.5B SEK
Loading...
US
Eli Lilly and Co
NYSE:LLY
978.7B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210B GBP
Loading...
CH
Novartis AG
SIX:NOVN
220.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
273B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
150.2B USD
Loading...
FR
Sanofi SA
PAR:SAN
95.7B EUR
Loading...

Market Distribution

Lower than 77% of companies in Sweden
Percentile
23nd
Based on 2 084 companies
23nd percentile
-30%
Low
-5 565 412.8% — -5.3%
Typical Range
-5.3% — 7.5%
High
7.5% — 12 228%
Distribution Statistics
Sweden
Min -5 565 412.8%
30th Percentile -5.3%
Median 3%
70th Percentile 7.5%
Max 12 228%

Calliditas Therapeutics AB
Glance View

Market Cap
1.1B USD
Industry
Pharmaceuticals

Calliditas Therapeutics AB, a biopharmaceutical company based in Sweden, has carved a niche for itself in the realm of specialty pharmaceuticals, particularly focusing on rare diseases. The company stands out with its dedication to developing novel treatments for orphan conditions that traditionally go under-addressed by larger pharmaceutical entities. Pivotal to its identity, Calliditas leverages its expertise in renal and hepatic diseases, emphasizing precision medicine aimed at improving the lives of patients with severe unmet medical conditions. Their flagship product, Nefecon, is a testament to their approach—designed to treat primary IgA nephropathy, a debilitating kidney disorder. By developing Nefecon with a patient-centric mindset, Calliditas aims to transform the treatment landscape, showcasing its commitment to innovation and regulatory expertise. Revenue generation at Calliditas primarily revolves around the commercialization of its niche therapeutic solutions. The company operates through a well-structured business model that includes strategic partnerships, licensing agreements, and direct market entry. Profits are garnered through successfully translating their clinical research into approved drugs that address critical needs in the healthcare sector. In tandem with developing their portfolio, Calliditas maximizes opportunities within established and emerging markets, ensuring that their highly specialized medicines reach the patients who need them most. This strategic focus not only secures their financial standing but also emphasizes their pivotal role as a pivotal player in rare disease treatment. The resultant revenue stream and successful collaborations underscore Calliditas's capability to marry scientific advancement with commercial viability, ensuring sustainable growth in a competitive pharmaceutical landscape.

CALT Intrinsic Value
125.4909 USD
Undervaluation 68%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-30%
=
Net Income
kr-480.4m
/
Revenue
kr1.6B
What is Calliditas Therapeutics AB's current Net Margin?

The current Net Margin for Calliditas Therapeutics AB is -30%, which is above its 3-year median of -37.9%.

How has Net Margin changed over time?

Over the last 3 years, Calliditas Therapeutics AB’s Net Margin has increased from -150 037% to -30%. During this period, it reached a low of -150 037% on Jun 30, 2021 and a high of -25.4% on Jun 30, 2023.

Back to Top